The Role of Neurotransmitters in Bipolar Disorder: Dopamine, Serotonin, Norepinephrine, GABA, and Glutamate

Written by
Amanda Snow
Published on
January 23, 2025
 • 
10
min read
Last reviewed
November 7, 2026
by
Justin Ray
A computer generated image of a human brain

Article Overview

When diagnosing bipolar disorder, one of the most common questions from clients is, "Do you think I'm crazy?" The answer is a resounding no. Bipolar disorder, like all psychiatric conditions, is rooted in the biology of the brain, and part of that biology involves neurotransmitters, the chemical messengers neurons use to communicate. This article explains what is actually known about five of them in bipolar disorder, where the evidence is strong and where it is unsettled, and how that knowledge shapes the medications we use.

One caution up front: the phrase "chemical imbalance" is everywhere online. Neurotransmitters matter in bipolar disorder, but the condition is not caused by too little or too much of a single chemical, and no blood test can measure your brain's neurotransmitter levels. We return to this below.

Which neurotransmitters are involved in bipolar disorder, and what they do

Psychiatry has traditionally focused on five primary neurotransmitters: dopamine, serotonin, norepinephrine, glutamate, and gamma-aminobutyric acid (GABA). The table summarizes what each does and what research most consistently shows in bipolar disorder.

NeurotransmitterNormal roleMost consistent finding in bipolar disorderMedications that act on it
DopamineReward, motivation, salienceIncreased signaling (higher D2/D3 receptor availability) in mania; increased dopamine transporter levels in bipolar depressionAntipsychotics, lithium
SerotoninMood, sleep, appetite, impulse controlReduced activity in bipolar depression and possibly between episodes; inconsistent in maniaLithium, quetiapine, lurasidone, lumateperone, cariprazine; antidepressants (cautiously)
NorepinephrineArousal, alertness, stress responseBreakdown product (MHPG) higher in mania and lower in depression in older studies; variableLithium, some antipsychotics; bupropion and SNRIs (cautiously)
GABAThe brain's main inhibitory "brake"Mixed: some tissue studies suggest reduced signaling, but imaging meta-analyses show no consistent deficitValproate, benzodiazepines (short term)
GlutamateThe brain's main excitatory "accelerator"; plasticityElevated glutamate-plus-glutamine (Glx) on brain spectroscopy across mood statesLamotrigine, lithium, valproate; ketamine (investigational)

Dopamine and bipolar disorder

Dopamine, the neurotransmitter of reward, motivation, and salience, has the strongest and longest-standing link to bipolar disorder, and the dopamine hypothesis remains the leading neurochemical model of the illness (Ashok et al., 2017).

  • In mania: Pharmacology and brain imaging converge on excess dopamine signaling, specifically elevated D2/D3 receptor availability and an overactive reward network. That fits the elevated mood, surging energy, grandiosity, reduced need for sleep, and risk-taking of mania, and it explains why stimulants and levodopa can trigger mania while dopamine-blocking antipsychotics are among the fastest treatments for it.
  • In bipolar depression: Imaging shows increased dopamine transporter levels, which would clear dopamine from the synapse faster and could help explain the loss of motivation, pleasure, and energy.
  • Across diagnoses: A PET study found striatal dopamine synthesis capacity elevated to a similar degree in bipolar disorder with psychosis and in schizophrenia, tracking psychotic symptoms regardless of diagnosis (Jauhar et al., 2017).

Ashok and colleagues proposed that bipolar disorder may reflect a failure of the balance between dopamine receptors and transporters: rising receptor availability tips toward mania, rising transporter levels toward depression. It is a model, not a settled fact, but it is the most useful single framework for why one illness produces opposite states.

Serotonin and bipolar disorder

Serotonin governs mood, sleep, appetite, and impulse control. In bipolar disorder its role is real but less distinctive than dopamine's. A review of the evidence concluded that central serotonergic activity is reduced during bipolar depression and also when people are well, suggesting low serotonin function may be a trait feature of the illness rather than a marker of current mood; findings in mania are inconsistent (Mahmood & Silverstone, 2001).

An older idea, the permissive hypothesis, proposed that low serotonin "permits" mood to swing in either direction, with the direction set by dopamine and norepinephrine (Prange et al., 1974). It is simplistic, but it captures something clinicians see daily: raising serotonin alone is often insufficient for bipolar depression and, in some people with bipolar I disorder, can precipitate mania or rapid cycling. This is why antidepressants are used cautiously in bipolar disorder and almost always alongside a mood stabilizer or antipsychotic.

Norepinephrine and bipolar disorder

Norepinephrine drives arousal, alertness, and the stress response. The original catecholamine hypothesis of mood disorders held that depression reflects a norepinephrine deficit at key synapses and mania an excess (Schildkraut, 1965). Decades of studies measuring its main breakdown product, MHPG, in urine and spinal fluid tended to support that direction, although results varied and the measures are indirect (Manji et al., 2003).

Clinically, norepinephrine's fingerprints are on the manic state: racing thoughts, restlessness, urgency, and the near-total loss of the need for sleep. The relationship runs both ways. Sleep deprivation, which ramps up noradrenergic arousal, is one of the most reliable triggers of mania, which is why protecting sleep is a first-line intervention rather than an afterthought.

GABA and bipolar disorder

GABA is the brain's primary inhibitory neurotransmitter, the brake on neuronal excitability. Intuitively a weak brake fits mania, and post-mortem studies have found reduced markers of GABA-producing interneurons in bipolar disorder (Benes & Berretta, 2001). The in-vivo evidence is less tidy: a meta-analysis of spectroscopy studies across seven psychiatric disorders found lower brain GABA in autism and current major depression but no significant difference in bipolar disorder (Schür et al., 2016), and one small study of stably treated people with bipolar I disorder found higher GABA than controls, with lower levels in those on GABA-modulating medications (Brady et al., 2013).

The honest summary is that GABA signaling is probably disturbed in bipolar disorder, but not in the simple "too little GABA" way often described. What is clear is that GABA-acting drugs work: valproate is an established antimanic agent, and benzodiazepines help short term with agitation and sleep during acute mania.

Glutamate and bipolar disorder

Glutamate is the brain's main excitatory neurotransmitter and the engine of learning and synaptic plasticity. Here the imaging evidence is more consistent. A meta-analysis found combined glutamate-plus-glutamine (Glx) elevated in bipolar disorder versus healthy controls across pooled brain regions, in both medicated and unmedicated participants, and in frontal regions in adults (Gigante et al., 2012). A later meta-analysis of the anterior cingulate cortex confirmed elevated Glx, found the increase was driven mainly by glutamine and most evident between episodes, and noted that mood stabilizers appeared to shift these levels (Scotti-Muzzi et al., 2021).

Excess glutamatergic activity is a plausible contributor to the racing, overdriven cognition of mania, and glutamate-modulating drugs are treatment mainstays. Lamotrigine blocks voltage-gated sodium channels and thereby reduces glutamate release, which is thought to underlie its value in preventing bipolar depression (Hahn et al., 2004); lithium and valproate also influence glutamate signaling. At the other end, ketamine, which acts on glutamate receptors, produced rapid antidepressant effects in bipolar depression in two National Institute of Mental Health randomized trials in which a single infusion was added to lithium or valproate (Diazgranados et al., 2010; Zarate et al., 2012); it remains an off-label, research-informed option rather than an approved treatment for bipolar depression.

Mania vs. bipolar depression: different chemistry?

To a degree, yes. Mania is best characterized as a high-dopamine, high-norepinephrine, high-arousal state with overactive reward circuitry and reduced inhibitory control. Bipolar depression looks more like a low-dopamine, low-serotonin, low-energy state, with increased dopamine transporter activity pulling dopamine out of circulation. Glutamate appears elevated across states, which may be part of why bipolar disorder is an illness of instability rather than a fixed deficit. This is also why bipolar depression is not treated like unipolar depression: the medications that work for both poles act on several systems at once rather than pushing one transmitter in one direction.

Is bipolar disorder a chemical imbalance?

Not in the way the phrase implies. "Chemical imbalance" suggests a single neurotransmitter that is too high or too low and a medication that tops it up, like insulin for diabetes. That is not an accurate picture of bipolar disorder, and clinicians have largely moved away from it. What the evidence supports instead:

  • Genetics. Bipolar disorder is one of the most heritable psychiatric conditions. Large genetic studies implicate many risk genes of small effect, including voltage-gated calcium channel genes such as CACNA1C that regulate neuronal excitability, rather than genes for a single neurotransmitter (Harrison et al., 2018).
  • Cellular signaling and energy. Disturbed calcium signaling inside neurons, mitochondrial dysfunction, and oxidative stress appear to be upstream contributors that secondarily destabilize serotonin, dopamine, and glutamate systems (Kato, 2019).
  • Circuits, not just chemicals. Imaging consistently shows altered communication between prefrontal regions that regulate emotion and limbic regions, such as the amygdala and striatum, that generate it. Neurotransmitters are the medium of that communication; the problem is better understood at the level of the circuit.
  • Rhythms and stress. Circadian disruption, sleep loss, substance use, and life stress interact with the underlying vulnerability to trigger episodes (McIntyre et al., 2020; Nierenberg et al., 2023).

So is bipolar depression a chemical imbalance? It involves measurable changes in neurotransmitter function, but it is more accurate to call it a disorder of brain circuits and cellular signaling with a strong genetic basis. That framing is more correct and less stigmatizing: bipolar disorder is neither a character flaw nor something a person can "balance" through willpower, and it is certainly not a result of being "crazy."

How this neurobiology guides medication choices

Every effective bipolar medication acts on several of the systems above at once, which is what you would predict for an illness that is not a single-transmitter problem.

  • Lithium remains the reference standard for long-term mood stabilization and the only agent with robust evidence for reducing suicide risk. Its mechanisms are intracellular, including GSK-3β inhibition, dampened inositol signaling, and neuroprotective effects, with downstream effects on dopamine, serotonin, and glutamate (Malhi et al., 2013).
  • Lamotrigine reduces glutamate release and is most useful for preventing depressive episodes; it does little for acute mania.
  • Valproate increases GABA availability and blocks sodium channels, making it an effective antimanic agent.
  • Second-generation antipsychotics block or partially activate dopamine D2 receptors, which treats mania, and most also act on serotonin receptors, which is thought to contribute to their effect on bipolar depression. Quetiapine, lurasidone (Loebel et al., 2014), cariprazine (approved for bipolar I depression in 2019), and lumateperone (Calabrese et al., 2021) all have FDA approval and trial evidence for bipolar depression. Lumateperone is notable for simultaneous dopamine, serotonin, and glutamate modulation with little weight gain or movement side effects; we review the evidence in Caplyta in bipolar depression: when efficacy meets tolerability.
  • Antidepressants that raise serotonin or norepinephrine alone are used sparingly, paired with a mood stabilizer, and avoided in people with a history of antidepressant-induced mania or rapid cycling.

Choosing among these depends on which pole dominates, past response, side-effect priorities, and medical history, which is why careful diagnosis and ongoing monitoring matter more than any single prescription. Learn how we approach bipolar disorder treatment in Chesapeake, and, because the two are frequently confused, read our comparison of bipolar disorder and borderline personality disorder.

Frequently asked questions

Too much of which neurotransmitter may be associated with mania?

Dopamine. Excess dopamine signaling, particularly increased D2/D3 receptor availability in reward circuits, is the finding most consistently linked to mania. Norepinephrine is also typically elevated in mania, and drugs that raise either transmitter can trigger it in susceptible people.

Which neurotransmitters are found at relatively high levels in both schizophrenia and bipolar disorder?

Dopamine. PET imaging shows elevated striatal dopamine synthesis capacity in both schizophrenia and bipolar disorder with psychosis. Elevated glutamate signaling has also been reported in both, which is why glutamate is sometimes given as a second answer.

What neurotransmitter causes mania?

No single neurotransmitter causes mania, but dopamine is the one most directly involved, with norepinephrine close behind. Mania is best understood as overactive dopamine and norepinephrine signaling with reduced inhibitory control, triggered in a vulnerable brain by sleep loss, stress, stimulants, or antidepressants.

Is bipolar depression a chemical imbalance?

Not in the simple sense. Bipolar depression involves measurable changes, including reduced dopamine and serotonin signaling, but it is more accurately a disorder of brain circuits and cellular signaling with a strong genetic basis. No single chemical is "low," and no blood test can measure brain neurotransmitter levels.

Is bipolar disorder caused by low serotonin?

No. Serotonin activity does appear reduced during bipolar depression and possibly between episodes, but low serotonin does not cause bipolar disorder, and raising serotonin alone with an SSRI is often ineffective and can occasionally trigger mania.

Why can antidepressants trigger mania in bipolar disorder?

Antidepressants increase serotonin, norepinephrine, or dopamine signaling. In a brain prone to swinging toward the high-dopamine, high-norepinephrine state of mania, that push can tip it over, especially in bipolar I disorder and without a mood stabilizer. This is why bipolar depression is usually treated first with lithium, lamotrigine, or an antipsychotic with antidepressant properties.

Talk to a provider

Understanding the neurobiology is only part of the picture; treatment depends on careful diagnosis and ongoing monitoring. If you or someone you love is living with mood episodes and wants a clear explanation and a thoughtful plan, schedule a consultation at South Chesapeake Psychiatry or call 757-908-2124. This article is educational and is not a substitute for individualized medical advice. If you are in crisis or thinking about harming yourself, call or text 988 to reach the Suicide and Crisis Lifeline.

References

Ashok, A. H., Marques, T. R., Jauhar, S., Nour, M. M., Goodwin, G. M., Young, A. H., & Howes, O. D. (2017). The dopamine hypothesis of bipolar affective disorder: The state of the art and implications for treatment. Molecular Psychiatry, 22(5), 666–679. https://pubmed.ncbi.nlm.nih.gov/28289283/

Benes, F. M., & Berretta, S. (2001). GABAergic interneurons: Implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology, 25(1), 1–27. https://pubmed.ncbi.nlm.nih.gov/11377916/

Brady, R. O., Jr., McCarthy, J. M., Prescot, A. P., Jensen, J. E., Cooper, A. J., Cohen, B. M., Renshaw, P. F., & Öngür, D. (2013). Brain gamma-aminobutyric acid (GABA) abnormalities in bipolar disorder. Bipolar Disorders, 15(4), 434–439. https://pubmed.ncbi.nlm.nih.gov/23634979/

Calabrese, J. R., Durgam, S., Satlin, A., Vanover, K. E., Davis, R. E., Chen, R., Kozauer, S. G., Mates, S., & Sachs, G. S. (2021). Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: A phase 3 randomized placebo-controlled trial. American Journal of Psychiatry, 178(12), 1098–1106. https://pubmed.ncbi.nlm.nih.gov/34551584/

Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., Machado-Vieira, R., Manji, H. K., & Zarate, C. A., Jr. (2010). A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry, 67(8), 793–802. https://pubmed.ncbi.nlm.nih.gov/20679587/

Gigante, A. D., Bond, D. J., Lafer, B., Lam, R. W., Young, L. T., & Yatham, L. N. (2012). Brain glutamate levels measured by magnetic resonance spectroscopy in patients with bipolar disorder: A meta-analysis. Bipolar Disorders, 14(5), 478–487. https://pubmed.ncbi.nlm.nih.gov/22834460/

Hahn, C. G., Gyulai, L., Baldassano, C. F., & Lenox, R. H. (2004). The current understanding of lamotrigine as a mood stabilizer. Journal of Clinical Psychiatry, 65(6), 791–804. https://pubmed.ncbi.nlm.nih.gov/15291656/

Harrison, P. J., Geddes, J. R., & Tunbridge, E. M. (2018). The emerging neurobiology of bipolar disorder. Trends in Neurosciences, 41(1), 18–30. https://pubmed.ncbi.nlm.nih.gov/29169634/

Jauhar, S., Nour, M. M., Veronese, M., Rogdaki, M., Bonoldi, I., Azis, M., Turkheimer, F., McGuire, P., Young, A. H., & Howes, O. D. (2017). A test of the transdiagnostic dopamine hypothesis of psychosis using positron emission tomographic imaging in bipolar affective disorder and schizophrenia. JAMA Psychiatry, 74(12), 1206–1213. https://pubmed.ncbi.nlm.nih.gov/29049482/

Kato, T. (2019). Current understanding of bipolar disorder: Toward integration of biological basis and treatment strategies. Psychiatry and Clinical Neurosciences, 73(9), 526–540. https://pubmed.ncbi.nlm.nih.gov/31021488/

Loebel, A., Cucchiaro, J., Silva, R., Kroger, H., Hsu, J., Sarma, K., & Sachs, G. (2014). Lurasidone monotherapy in the treatment of bipolar I depression: A randomized, double-blind, placebo-controlled study. American Journal of Psychiatry, 171(2), 160–168. https://pubmed.ncbi.nlm.nih.gov/24170180/

Mahmood, T., & Silverstone, T. (2001). Serotonin and bipolar disorder. Journal of Affective Disorders, 66(1), 1–11. https://pubmed.ncbi.nlm.nih.gov/11532527/

Malhi, G. S., Tanious, M., Das, P., Coulston, C. M., & Berk, M. (2013). Potential mechanisms of action of lithium in bipolar disorder: Current understanding. CNS Drugs, 27(2), 135–153. https://pubmed.ncbi.nlm.nih.gov/23371914/

Manji, H. K., Quiroz, J. A., Payne, J. L., Singh, J., Lopes, B. P., Viegas, J. S., & Zarate, C. A. (2003). The underlying neurobiology of bipolar disorder. World Psychiatry, 2(3), 136–146. https://pubmed.ncbi.nlm.nih.gov/16946919/

McIntyre, R. S., Berk, M., Brietzke, E., Goldstein, B. I., López-Jaramillo, C., Kessing, L. V., Malhi, G. S., Nierenberg, A. A., Rosenblat, J. D., Majeed, A., Vieta, E., Vinberg, M., Young, A. H., & Mansur, R. B. (2020). Bipolar disorders. The Lancet, 396(10265), 1841–1856. https://pubmed.ncbi.nlm.nih.gov/33278937/

Nierenberg, A. A., Agustini, B., Köhler-Forsberg, O., Cusin, C., Katz, D., Sylvia, L. G., Peters, A., & Berk, M. (2023). Diagnosis and treatment of bipolar disorder: A review. JAMA, 330(14), 1370–1380. https://pubmed.ncbi.nlm.nih.gov/37815563/

Prange, A. J., Jr., Wilson, I. C., Lynn, C. W., Alltop, L. B., & Stikeleather, R. A. (1974). L-tryptophan in mania: Contribution to a permissive hypothesis of affective disorders. Archives of General Psychiatry, 30(1), 56–62. https://pubmed.ncbi.nlm.nih.gov/4587067/

Schildkraut, J. J. (1965). The catecholamine hypothesis of affective disorders: A review of supporting evidence. American Journal of Psychiatry, 122(5), 509–522. (Reprinted 1995, Journal of Neuropsychiatry and Clinical Neurosciences, 7(4), 524–533. https://pubmed.ncbi.nlm.nih.gov/8555758/)

Schür, R. R., Draisma, L. W., Wijnen, J. P., Boks, M. P., Koevoets, M. G., Joëls, M., Klomp, D. W., Kahn, R. S., & Vinkers, C. H. (2016). Brain GABA levels across psychiatric disorders: A systematic literature review and meta-analysis of 1H-MRS studies. Human Brain Mapping, 37(9), 3337–3352. https://pubmed.ncbi.nlm.nih.gov/27145016/

Scotti-Muzzi, E., Umla-Runge, K., & Soeiro-de-Souza, M. G. (2021). Anterior cingulate cortex neurometabolites in bipolar disorder are influenced by mood state and medication: A meta-analysis of 1H-MRS studies. European Neuropsychopharmacology, 47, 62–73. https://pubmed.ncbi.nlm.nih.gov/33581932/

Zarate, C. A., Jr., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012). Replication of ketamine's antidepressant efficacy in bipolar depression: A randomized controlled add-on trial. Biological Psychiatry, 71(11), 939–946. https://pubmed.ncbi.nlm.nih.gov/22297150/

Reviewed and updated by Justin Ray, MSN, PMHNP-BC — November 7, 2026

Take the first step towards medication and care that can help you feel better.

Schedule an appointment today to get diagnosed, receive a prescription, and continue your journey towards mental peace.

The lobby of South Chesapeake Psychiatry with seating and a front desk.